Literature DB >> 7488811

Intermittent treatment with inhaled steroids for deterioration of asthma due to upper respiratory tract infections.

J Svedmyr1, E Nyberg, E Asbrink-Nilsson, G Hedlin.   

Abstract

Upper respiratory tract infection (URTI) is a common cause of deterioration of asthma in children. We investigated if inhaled steroids (budesonide), started early after URTI, could reduce asthma. Thirty-one children, 3-10 years of age, with deterioration during URTI participated. The study design was double-blind, crossover and placebo-controlled. Peak-expiratory flow (PEF) and symptom scores were recorded. Four treatment periods of 9 days, two with budesonide and two with placebo, were planned. Treatment was started at the first sign of URTI. Budesonide/placebo was given by Turbuhaler at 0.2 mg qid for 3 days, tid for 3 and bid for the last 3 days. Twenty-two children completed 67 periods. Eleven visited the emergency room, only three during budesonide therapy. Five received oral steroids and two where admitted to hospital, all receiving placebo. Symptom scores were not significantly lower during budesonide treatment. PEF, both morning and evening, was significantly higher during budesonide than placebo (p = 0.015 and p = 0.022). Inhaled budesonide can attenuate exacerbation of URTI-induced asthma.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7488811     DOI: 10.1111/j.1651-2227.1995.tb13786.x

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  11 in total

1.  As Needed Use of Inhaled Corticosteroids for Management of Mild Persistent Asthma in Children.

Authors:  Hengameh H Raissy; Kathryn Blake
Journal:  Pediatr Allergy Immunol Pulmonol       Date:  2011-12       Impact factor: 1.349

Review 2.  Summary of recommendations from the Canadian Asthma Consensus guidelines, 2003.

Authors:  Allan Becker; Catherine Lemière; Denis Bérubé; Louis-Philippe Boulet; Francine M Ducharme; Mark FitzGerald; Thomas Kovesi
Journal:  CMAJ       Date:  2005-09-13       Impact factor: 8.262

3.  Pharmacotherapy--treatment of intermittent asthma with ICSs.

Authors: 
Journal:  CMAJ       Date:  2005-09-13       Impact factor: 8.262

Review 4.  Inhaled steroids for acute asthma following emergency department discharge.

Authors:  Marcia L Edmonds; Stephen J Milan; Barry E Brenner; Carlos A Camargo; Brian H Rowe
Journal:  Cochrane Database Syst Rev       Date:  2012-12-12

Review 5.  Increased versus stable doses of inhaled corticosteroids for exacerbations of chronic asthma in adults and children.

Authors:  Kayleigh M Kew; Ella Flemyng; Bradley S Quon; Clarus Leung
Journal:  Cochrane Database Syst Rev       Date:  2022-09-26

Review 6.  Management of Preschool Children with Recurrent Wheezing: Lessons from the NHLBI's Asthma Research Networks.

Authors:  Avraham Beigelman; Leonard B Bacharier
Journal:  J Allergy Clin Immunol Pract       Date:  2016 Jan-Feb

7.  Induction of B7-H1 and B7-DC expression on airway epithelial cells by the Toll-like receptor 3 agonist double-stranded RNA and human rhinovirus infection: In vivo and in vitro studies.

Authors:  Lowella Heinecke; David Proud; Scherer Sanders; Robert P Schleimer; Jean Kim
Journal:  J Allergy Clin Immunol       Date:  2008-04-18       Impact factor: 10.793

8.  Treatment of acute asthmatic exacerbations with an increased dose of inhaled steroid.

Authors:  J Garrett; S Williams; C Wong; D Holdaway
Journal:  Arch Dis Child       Date:  1998-07       Impact factor: 3.791

Review 9.  Increased versus stable doses of inhaled corticosteroids for exacerbations of chronic asthma in adults and children.

Authors:  Kayleigh M Kew; Michael Quinn; Bradley S Quon; Francine M Ducharme
Journal:  Cochrane Database Syst Rev       Date:  2016-06-07

10.  2003 canadian asthma consensus guidelines executive summary.

Authors:  Allan Becker; Catherine Lemière; Denis Bérubé; Louis-Philippe Boulet; Francine Ducharme; Mark Fitzgerald; Thomas Kovesi
Journal:  Allergy Asthma Clin Immunol       Date:  2006-03-15       Impact factor: 3.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.